Calyxt Inc. (NASDAQ: CLXT) stock jumped 11.03% on Friday to $0.26 against a previous-day closing price of $0.23. With 1.14 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.48 million shares. During the session, the Packaged Foods company that operates in wider Consumer Defensive sector, reached to the highest price of $0.2600 whereas the lowest price it dropped to was $0.2400. The 52-week range on CLXT shows that it touched its highest point at $4.43 and its lowest point at $0.20 during that stretch. It currently has a 1-year price target of $4.24. Beta for the stock currently stands at 2.07.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CLXT was up-trending over the past week, with a rise of 14.74%, but this was down by -0.54% over a month. Three-month performance dropped to -41.98% while six-month performance fell -86.22%. The stock lost -93.02% in the past year, while it has lost -87.91% so far this year. A look at the trailing 12-month EPS for CLXT yields -0.64 with Next year EPS estimates of -0.49. For the next quarter, that number is -0.14. This implies an EPS growth rate of 41.10% for this year and 12.50% for next year.
Float and Shares Shorts:
At present, 42.02 million CLXT shares are outstanding with a float of 26.00 million shares on hand for trading. On Jul 14, 2022, short shares totaled 57200.0, which was 0.13% higher than short shares on Jun 14, 2022. In addition to Mr. Michael Allen Carr as the firm’s Pres, CEO & Director, Mr. William F. Koschak serves as its Chief Financial Officer.
Through their ownership of 13.69% of CLXT’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 59.71% of CLXT, in contrast to 5.27% held by mutual funds. Shares owned by individuals account for 17.04%. As the largest shareholder in CLXT with 6.10% of the stake, Fidelity Management & Research Co holds 2,609,480 shares worth 2,609,480. A second-largest stockholder of CLXT, Armistice Capital LLC, holds 2,283,220 shares, controlling over 5.34% of the firm’s shares. Uniplan Investment Counsel, Inc. is the third largest shareholder in CLXT, holding 1,206,546 shares or 2.82% stake. With a 2.98% stake in CLXT, the Nikko Asset Global All-Biogenome is the largest stakeholder. A total of 1,272,162 shares are owned by the mutual fund manager. The Fidelity Growth Company Fund, which owns about 0.61% of CLXT stock, is the second-largest Mutual Fund holder. It holds 261,423 shares valued at 63264.0. Vanguard Extended Market Index Fu holds 0.45% of the stake in CLXT, owning 192,274 shares worth 46530.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CLXT since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CLXT analysts setting a high price target of $10.00 and a low target of $1.00, the average target price over the next 12 months is $4.88. Based on these targets, CLXT could surge 3746.15% to reach the target high and rise by 284.62% to reach the target low. Reaching the average price target will result in a growth of 1776.92% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CLXT will report FY 2022 earnings on 03/14/2023. Analysts have provided yearly estimates in a range of -$0.50 being high and -$0.56 being low. For CLXT, this leads to a yearly average estimate of -$0.54. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Calyxt Inc. surprised analysts by $0.04 when it reported -$0.14 EPS against a consensus estimate of -$0.17. The surprise factor in the prior quarter was $0.08. Based on analyst estimates, the high estimate for the next quarter is -$0.12 and the low estimate is -$0.15. The average estimate for the next quarter is thus -$0.14.
Summary of Insider Activity:
Insiders traded CLXT stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 4 over the past year. The total number of shares bought during that period was 1,023,800 while 27,280 shares were sold.